Akebia Therapeutics (NASDAQ: AKBA) reported Q4 EPS of ($0.79), $0.32 worse than the analyst estimate of ($0.47). Revenue for the quarter came in at $69.56 million versus the consensus estimate of $93.15 million.

For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.